CRL
HealthcareCharles River Laboratories International, Inc.
Key Drivers
- Margin Recovery
- Strong Cash Flow
- Rising Leverage
AIAI Summary
CRL is shifting from a cyclical biotech-recovery trade to an execution-driven operating turnaround, with strong DSA bookings and higher-margin specialized services offering upside, but its premium valuation and elevated leverage require sustained booking conversion, margin expansion, and deleveraging to justify owning the shares.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Strong Cash Flow
- •Rising Leverage
CRL's margins and free cash flow are improving, but elevated leverage, weak interest coverage, intangible-heavy assets, and demanding valuation keep the risk/reward profile unfavorable.
Price Behavior
Key Price Behavior Insights:
- •Negative momentum
- •Critical support
- •Elevated volatility
CRL is in a volatile short-term pullback, with $273 support critical and a reclaim of $280–$282 needed to signal stabilization.
Large daily swings signal elevated volatility risk
Sentiment & News
Key News Insights:
- •Capacity Expansion
- •Faster Cell Banking
- •Margin Pressure
Charles River's capacity expansion and faster cell-banking offerings support growth momentum, but premium valuation and margin/cost risks warrant caution.
The updates are broadly positive for CRL's growth outlook, though valuation and cost volatility may limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings